Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Net Cash Flow (2016 - 2025)

Creative Medical Technology Holdings has reported Net Cash Flow over the past 16 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Net Cash Flow rose 672.63% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 48.75% year-over-year, with the annual reading at $1.3 million for FY2025, 48.75% down from the prior year.
  • Net Cash Flow was $1.8 million for Q4 2025 at Creative Medical Technology Holdings, up from -$1.2 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $13.7 million in Q2 2022 and troughed at -$8.6 million in Q4 2022.
  • The 5-year median for Net Cash Flow is -$218291.0 (2021), against an average of $355505.7.
  • Peak annual rise in Net Cash Flow hit 131533.57% in 2021, while the deepest fall reached 8817.06% in 2021.
  • Tracing CELZ's Net Cash Flow over 5 years: stood at $8.3 million in 2021, then plummeted by 203.63% to -$8.6 million in 2022, then skyrocketed by 87.97% to -$1.0 million in 2023, then surged by 69.23% to -$320036.0 in 2024, then skyrocketed by 672.63% to $1.8 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $1.8 million, -$1.2 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.